Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of κB Kinase and Inflammasome-Mediated Interleukin-1β Secretion

  title={Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of $\kappa$B Kinase and Inflammasome-Mediated Interleukin-1$\beta$ Secretion},
  author={Hyun Young Kim and Kyeong Seok Kim and Myungyeon Kim and Hyung Shik Kim and Kwang Youl Lee and Keon Wook Kang},
  journal={Oxidative Medicine and Cellular Longevity},
Osteoporosis is a degenerative metabolic disease caused by an imbalance between osteogenesis and osteoclastogenesis. Increased levels of proinflammatory cytokines combined with decreased estrogen levels, which are commonly seen in postmenopausal women, can lead to overactivation of osteoclasts. Therefore, targeting osteoclast maturation may represent a novel strategy for both treating and preventing osteoporosis. Auranofin is a gold-based compound first approved in 1985 for the treatment of… 

Figures from this paper

NLRP3 Inflammasome: A New Target for Prevention and Control of Osteoporosis?
It is demonstrated that the NLRP3 inflammasome plays a vital role in the pathogenesis of osteoporosis by affecting the differentiation of osteoblasts and osteoclasts, and overall not only accelerates bone resorption, but also inhibits bone formation, thus increasing the risk of bone formation.
Inflammasomes in Alveolar Bone Loss
A framework for understanding the role and mechanism of canonical and noncanonical inflammasomes in the pathogenesis and development of etiologically diverse diseases associated with alveolar bone loss is presented.
Cytokines in Inflammatory Disease
This review aims to briefly discuss a short list of a broad variety of inflammatory cytokines, focusing on the correlations and role of these inflammatory mediators in the genesis of inflammatory impacts.
N‐[2‐(4‐benzoyl‐1‐piperazinyl)phenyl]‐2‐(4‐chlorophenoxy) acetamide is a novel inhibitor of resorptive bone loss in mice
PPOAC‐Bz altered the mRNA expressions of several osteoclast‐specific marker genes and blocked the formation of mature osteoclasts, suppressing F‐actin belt formation and bone resorption activity in vitro and prevented OVX‐induced bone loss in vivo.


Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo
Selective inhibition of NF-κB activation offers an effective therapeutic approach for inhibiting chronic inflammatory diseases involving bone resorption, and significantly reduced the severity of collagen-induced arthritis in mice.
The Mechanism of Osteoclast Differentiation Induced by IL-11
It is shown that IL-1 has the potential to drive osteoclast differentiation via a receptor activator of NF-κB ligand (RANKL)/RANK-independent mechanism and that IL/IL-1RI strongly activates MITF, which subsequently induces osteOClast-specific genes such as osteoc last-associated receptor and tartrate-resistant acid phosphatase.
IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss
IKKβ protects osteoclasts and their progenitors from tumor necrosis factor α–induced apoptosis, and its loss in hematopoietic cells prevents inflammation-induced bone loss.
Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-κB transactivation by RANKL
It is found that p38 MAPK upstream components transforming growth factor-beta-activated kinase 1 (TAK1), MKK3, and MKK6 increased by RANKL in an early stage of osteoclastogenesis from primary bone marrow cells, which led to enhanced p38 activation and p65 phosphorylation and NFATc1 induction.
Thiol-Reactive Metal Compounds Inhibit NF-κB Activation by Blocking IκB Kinase1
The effect of various gold compounds on the activation of NF-κB and IKK in LPS-stimulated RAW 264.7 mouse macrophages was tested and suggested the antiinflammatory activity of gold compounds in the treatment of rheumatoid arthritis may depend on modification of this thiol group by gold.
IL-1 mediates TNF-induced osteoclastogenesis.
IL-1 mediates the osteoclastogenic effect of TNF by enhancing stromal cell expression of RANKL and directly stimulating differentiation of osteoclass precursors under the aegis of p38 MAPK.
Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos*
In Fos-/- precursors gene transfer of an active form of NFAT restored transcription of osteoclast-specific genes in the presence of receptor activator of the NF-κB ligand, rescuing bone resorption and indicating that transcriptional induction of Nfatc1 is a major function of c-Fos in osteoc last differentiation.
Mst2 Controls Bone Homeostasis by Regulating Osteoclast and Osteoblast Differentiation
  • Jongwon Lee, B. U. Youn, Nacksung Kim
  • Biology
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2015
It is demonstrated that mice deficient in Mst2 exhibit osteoporotic phenotypes with increased numbers of osteoclasts and decreased number of osteoblasts as shown by micro–computed tomography (µCT) and histomorphometric analyses, and the NF‐κB pathway is activated by Mst 2 deficiency during osteoclast and osteoblast development.
Platycodin D Inhibits Osteoclastogenesis by Repressing the NFATc1 and MAPK Signaling Pathway
Interestingly, platycodin D, the most abundant and major pharmacological constituent of triterpenoid CKS, inhibited receptor activator of NF‐κB ligand (RANKL)‐induced activation of NF-κB, and ERK and p38 MAPK, and ultimately repressing osteoclast differentiation.